CD274 and non-small cell lung carcinoma: While PD-L1 scores from immunohistochemistry (IHC) may enrich prediction of response to ICB monotherapy or combination therapy in advanced NSCLC, some evidence suggests responders are not limited to those with high PD-L1 expression [8].